Clinical and Experimental Research Progress of Wulingsan in Treatment of Renal Diseases： A Review
10.13422/j.cnki.syfjx.20211391
- VernacularTitle:五苓散治疗肾系疾病临床及实验研究进展
- Author:
You-lan GONG
1
;
Hui-fen HUANG
1
;
Zhen LIU
1
;
Bin-cai WU
2
;
Tian-hao DENG
1
;
Tie-ru CAI
1
Author Information
1. Hunan Academy of Chinese Medicine，Changsha 410006， China
2. Changsha Social Work College，Changsha 410004， China
- Publication Type:Research Article
- Keywords:
Wulingsan;
renal diseases;
clinical research;
experimental research;
research progress
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(13):199-206
- CountryChina
- Language:Chinese
-
Abstract:
Wulingsan， a classic prescription first recorded in the Treatise on Cold Damage （Shang Han Lun） by ZHANG Zhong-jing for patients with water retention syndrome due to the disturbance of Qi transformation in bladder， has often been modified by ancient and modern doctors for the treatment of renal diseases. It produced satisfactory outcomes without inducing adverse reactions. The databases including China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform， and PubMed were searched for articles concerning the clinical application and pharmacological mechanism of Wulingsan in the treatment of renal diseases published by domestic and foreign scholars in recent years. The summary of the included articles revealed that Wulingsan has been widely employed for the treatment of renal edema， diabetic nephropathy， acute and chronic glomerulonephritis， nephrotic syndrome， renal insufficiency， abnormal urination， etc.， and the resulting outcomes were satisfactory. Wulingsan alone or in combination with western medicine yielded better clinical outcomes than the western medicine alone. In the exploration of its pharmacological mechanism， there existed some individual reports by Korean scholars， while Chinese scholars tended to work as a team. After years of research， each team has found that Wulingsan was superior to Wulingsan decoction in excreting water， which might be related to the absence of massive low-polarity and volatile components in the decoction that were responsible for regulating the expression of aquaporins （AQP） in kidney of saline-loaded rats. Wulingsan regulates the endocrine state of rats with kidney yang deficiency， inhibits the reabsorption of water， increases the activity of Na+-K+-ATPase， and reduces the expression of AQP 1， AQP 2， AQP 3， and AQP 4. Besides， it bi-directionally regulates the human water metabolism， which is achieved via the dual-directional regulation of purinergic P2X3 receptor expression on bladder detrusor. The efficacy of Wulingsan in treating chronic renal failure is attributed to its protection against the damaged renal tissue，structure and fanction. Hence， this paper summarized the research progress of Wulingsan in the treatment of renal diseases in recent years， aiming to provide a reference for the clinical and basic exploration of Wulingsan against renal diseases in the future.
